Abstract
Pyrrolizidine alkaloids (PAs) are widely distributed natural toxins and have been extensively studied for their hepatotoxicity. However, PA-induced pulmonary toxicity remains less studied regarding the initiating mechanism and treatment approaches. Our previous study demonstrated the formation of pyrrole–hemoglobin adducts after PA exposure in vivo, which is suspected to affect the oxygen-carrying capacity of erythrocytes [red blood cells (RBCs)] consequently. The present study aimed to investigate the effects of PAs on the oxygen-carrying capacity of RBCs and the potential of targeting RBC-mediated hypoxia to alleviate PA-induced lung injury. First, rats were treated with retrorsine (RTS) or monocrotaline (MCT) intravenously at 0.2 mmol/kg. The results of Raman spectrometry analysis on blood samples revealed both RTS and MCT significantly reduced the oxygen-carrying capacity of RBCs. Further, MCT (0.2 mmol/kg) was orally given to the rats with or without pretreatment with two doses of erythropoietin (Epo, 500 IU/kg/dose every other day), an RBC-stimulating agent. Biochemical and histological results showed pretreatment with Epo effectively reduced the cardiopulmonary toxicity induced by MCT. These findings provide the first evidence that adduction on hemoglobin, and the resulting RBC damage and impaired oxygen-carrying capacity, are the major initiating mechanism underlying PA-induced pulmonary arterial hypertension (PAH), while targeting the RBC damage is a potential therapeutic approach for PA-induced lung injury.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.
References
Bhat L, Hawkinson J, Cantillon M et al (2017) RP5063, a novel, multimodal, serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats. Eur J Pharmacol 810:92–99. https://doi.org/10.1016/j.ejphar.2017.05.048
Burton VJ, Holmes AM, Ciuclan LI et al (2011) Attenuation of leukocyte recruitment via CXCR1/2 inhibition stops the progression of PAH in mice with genetic ablation of endothelial BMPR-II. Blood 118(17):4750–4758. https://doi.org/10.1182/blood-2011-05-347393
Castagnoli N, Rimoldi JM, Bloomquist J, Castagnoli KP (1997) Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. Chem Res Toxicol 10(9):924–940. https://doi.org/10.1021/tx970096j
Dumitrascu R, Koebrich S, Dony E et al (2008) Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. BMC Pulm Med 8:25. https://doi.org/10.1186/1471-2466-8-25
Edgar JA, Molyneux RJ, Colegate SM (2015) Pyrrolizidine Alkaloids: potential role in the etiology of cancers, pulmonary hypertension, congenital anomalies, and liver disease. Chem Res Toxicol 28(1):4–20. https://doi.org/10.1021/tx500403t
Endo Y, Torii R, Yamazaki F et al (2001) Water drinking causes a biphasic change in blood composition in humans. Pflugers Arch 442(3):362–368. https://doi.org/10.1007/s004240100555
Fu PP, Xia QS, Chou MW, Lin G (2007) Detection, hepatotoxicity, and tumorigenicity of pyrrolizidine alkaloids in Chinese herbal plants and herbal dietary supplements. J Food Drug Anal 15(4):400–415
Gillis CN, Huxtable RJ, Roth RA (1978) Effects of monocrotaline pretreatment of rats on removal of 5-hydroxytryptamine and noradrenaline by perfused lung. Br J Pharmacol 63(3):435–443. https://doi.org/10.1111/j.1476-5381.1978.tb07795.x
Gyorik S, Stricker H (2009) Severe pulmonary hypertension possibly due to pyrrolizidine alkaloids in polyphytotherapy. Swiss Med Wkly 139(13–14):210–211
He Y, Lian W, Ding L et al (2021) Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites. Arch Toxicol 95(1):103–116. https://doi.org/10.1007/s00204-020-02921-0
Heath D, Shaba J, Williams A, Smith P, Kombe A (1975) A pulmonary hypertension-producing plant from Tanzania. Thorax 30(4):399–404. https://doi.org/10.1136/thx.30.4.399
Hill NS, Gillespie MN, McMurtry IF (2017) Fifty years of monocrotaline-induced pulmonary hypertension: what has it meant to the field? Chest 152(6):1106–1108. https://doi.org/10.1016/j.chest.2017.10.007
Hu SZ, Smith KM, Spiro TG (1996) Assignment of protoheme resonance raman spectrum by heme labeling in myoglobin. J Am Chem Soc 118(50):12638–12646. https://doi.org/10.1021/ja962239e
Lin G, Wang JY, Li N et al (2011) Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol 54(4):666–673. https://doi.org/10.1016/j.jhep.2010.07.031
Ma J, Ruan J, Chen X et al (2019) Pyrrole-Hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol 32(6):1027–1039. https://doi.org/10.1021/acs.chemrestox.8b00369
Ma J, Zhang W, He YS et al (2021) Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Arch Toxicol 95(2):759–765. https://doi.org/10.1007/s00204-020-02947-4
Machogu EM, Machado RF (2018) How I treat hypoxia in adults with hemoglobinopathies and hemolytic disorders. Blood 132(17):1770–1780. https://doi.org/10.1182/blood-2018-03-818195
Marengo-Rowe AJ (2006) Structure-Function Relations of Human Hemoglobins. Proc (bayl Univ Med Cent) 19(3):239–245. https://doi.org/10.1080/08998280.2006.11928171
Nemecek D, Stepanek J, Thomas GJ Jr (2013) Raman spectroscopy of proteins and nucleoproteins. Curr Protoc Protein Sci Chapter 17(Unit17):8. https://doi.org/10.1002/0471140864.ps1708s71
Pan L, Lame MW, Morin D, Wilson DW, Segall HJ (1991) Red-Blood-cells augment transport of reactive metabolites of monocrotaline from liver to lung in isolated and tandem liver and lung preparations. Toxicol Appl Pharm 110(2):336–346. https://doi.org/10.1016/S0041-008x(05)80016-X
Preston IR (2007) Clinical perspective of hypoxia-mediated pulmonary hypertension. Antioxid Redox Signal 9(6):711–721. https://doi.org/10.1089/ars.2007.1587
Robertson KA, Seymour JL, Hsia MT, Allen JR (1977) Covalent interaction of dehydroretronecine, a carcinogenic metabolite of the pyrrolizidine alkaloid monocrotaline, with cysteine and glutathione. Cancer Res 37(9):3141–3144
Ruan J, Yang M, Fu P, Ye Y, Lin G (2014) Metabolic Activation of Pyrrolizidine Alkaloids: insights into the structural and enzymatic basis. Chem Res Toxicol 27(6):1030–1039. https://doi.org/10.1021/tx500071q
Ruan J, Gao H, Li N et al (2015) Blood Pyrrole-protein adducts–a biomarker of pyrrolizidine alkaloid-induced liver injury in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 33(4):404–421. https://doi.org/10.1080/10590501.2015.1096882
Sadowska O, Baranowska-Kuczko M, Gromotowicz-Poplawska A et al (2020) Cannabidiol Ameliorates monocrotaline-induced pulmonary hypertension in rats. Int J Mol Sci. https://doi.org/10.3390/ijms21197077
Sajkov D, Petrovsky N, Palange P (2010) Management of dyspnea in advanced pulmonary arterial hypertension. Curr Opin Support Palliat Care 4(2):76–84. https://doi.org/10.1097/SPC.0b013e328338c1e0
Sasaki R, Masuda S, Nagao M (2000) Erythropoietin: multiple physiological functions and regulation of biosynthesis. Biosci Biotechnol Biochem 64(9):1775–1793. https://doi.org/10.1271/bbb.64.1775
Schrenk D (2020) Toxicology of pyrrolizidine alkaloids. Food Chem Toxicol. https://doi.org/10.1016/j.fct.2019.110938
Schrenk D, Gao L, Lin G et al (2020) Pyrrolizidine alkaloids in food and phytomedicine: occurrence, exposure, toxicity, mechanisms, and risk assessment - A review. Food Chem Toxicol 136:111107. https://doi.org/10.1016/j.fct.2019.111107
Shi R, Wei Z, Zhu D et al (2018) Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats. Pulm Pharmacol Ther 48:124–135. https://doi.org/10.1016/j.pupt.2017.11.003
Song J, Sundar KM, Hoidal J, Prchal JT (2019) Hematological changes in chronic sustained hypoxia and chronic intermittent hypoxia in a mouse model. Blood. https://doi.org/10.1182/blood-2019-131309
Song Z, He YS, Ma J, Fu PP, Lin G (2020) Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids. J Env Sci Heal C-Tox 38(2):124–140. https://doi.org/10.1080/26896583.2020.1743608
Spiro TG, Strekas TC (1972) Resonance raman spectra of hemoglobin and cytochrome c: inverse polarization and vibronic scattering. Proc Natl Acad Sci U S A 69(9):2622–2626. https://doi.org/10.1073/pnas.69.9.2622
Tartavoulle TM, Karpinski AC, Aubin A, Kluger BM, Distler O, Saketkoo LA (2018) Multidimensional fatigue in pulmonary hypertension: prevalence, severity and predictors. ERJ Open Res. https://doi.org/10.1183/23120541.00079-2017
Torres IP, Terner J, Pittman RN, Proffitt E, Ward KR (2008) Measurement of hemoglobin oxygen saturation using Raman microspectroscopy and 532-nm excitation. J Appl Physiol 104(6):1809–1817. https://doi.org/10.1152/japplphysiol.00025.2008
Wood BR, McNaughton D (2002) Raman excitation wavelength investigation of single red blood cells in vivo. J Raman Spectrosc 33(7):517–523. https://doi.org/10.1002/jrs.870
Yang M, Ruan J, Fu PP, Lin G (2016) Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity. Chem Biol Interact 243:119–126. https://doi.org/10.1016/j.cbi.2015.09.011
Yang M, Ruan J, Gao H et al (2017) First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans. Arch Toxicol 91(12):3913–3925. https://doi.org/10.1007/s00204-017-2013-y
Yang M, Ma J, Ruan J, Ye Y, Fu PP, Lin G (2019) Intestinal and hepatic biotransformation of pyrrolizidine alkaloid N-oxides to toxic pyrrolizidine alkaloids. Arch Toxicol 93(8):2197–2209. https://doi.org/10.1007/s00204-019-02499-2
Zhu L, Zhang CY, Li DP et al (2021) Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacol Sin 42(8):1212–1222. https://doi.org/10.1038/s41401-020-00553-9
Acknowledgements
The present study was supported by Research Grant Council of Hong Kong (Grant No. 14160817).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Song, Z., Lian, W., He, Y. et al. Targeting erythrocyte-mediated hypoxia to alleviate lung injury induced by pyrrolizidine alkaloids. Arch Toxicol 97, 819–829 (2023). https://doi.org/10.1007/s00204-023-03443-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-023-03443-1